Evidence map›Paper›PMID 35896565›Full record

ArticleScientific reports2022

Pharmacological sequestration of mitochondrial calcium uptake protects against dementia and β-amyloid neurotoxicity.

Elena F Shevtsova, Plamena R Angelova, Olga A Stelmashchuk, Noemi Esteras, Nataliia A Vasil'eva, Andrey V Maltsev, Pavel N Shevtsov, Alexander V Shaposhnikov, Vladimir P Fisenko, Sergey O Bachurin and 1 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Organelle abnormalities in Alzheimer's disease.Organelle (Tucson, Ariz.) · 2025
    Article
  7. Review
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Elena F ShevtsovaInstitute of Physiologically Active Compounds Russian Academy of Science, Chernogolovka, Moscow Region, Russia. shevtsova@ipac.ac.ru.ORCID 0000-0003-2887-1185
Plamena R AngelovaDepartment of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, WC1N 3BG, UK.ORCID 0000-0003-4596-9117
Olga A StelmashchukCell Physiology and Pathology Laboratory, Orel State University, Orel, Russia.
Noemi EsterasDepartment of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, WC1N 3BG, UK.ORCID 0000-0002-7938-6131
Nataliia A Vasil'evaInstitute of Physiologically Active Compounds Russian Academy of Science, Chernogolovka, Moscow Region, Russia.ORCID 0000-0002-2173-6135
Andrey V MaltsevInstitute of Physiologically Active Compounds Russian Academy of Science, Chernogolovka, Moscow Region, Russia.ORCID 0000-0002-1956-0839
Pavel N ShevtsovInstitute of Physiologically Active Compounds Russian Academy of Science, Chernogolovka, Moscow Region, Russia.ORCID 0000-0001-5960-3680
Alexander V ShaposhnikovDepartment of Analysis and Forecasting of Biomedical Health Risks, Centre for Strategic Planning of FMBA of Russia, Moscow, Russia.ORCID 0000-0003-4851-4775
Vladimir P FisenkoI.M. Sechenov First Moscow State Medical University, Moscow, Russia.ORCID 0000-0002-9080-5763
Sergey O BachurinInstitute of Physiologically Active Compounds Russian Academy of Science, Chernogolovka, Moscow Region, Russia.ORCID 0000-0003-3637-818X
Andrey Y AbramovDepartment of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, WC1N 3BG, UK.ORCID 0000-0002-7646-7235
Institute of Physiologically Active Compounds · RUNational Hospital for Neurology and Neurosurgery · GBCenter for Strategic Research · RUOrel State University named after I.S. Turgenev · RUSechenov University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

All forms of dementia including Alzheimer's disease are currently incurable. Mitochondrial dysfunction and calcium alterations are shown to be involved in the mechanism of neurodegeneration in Alzheimer's disease. Previously we have described the ability of compound Tg-2112x to protect neurons via sequestration of mitochondrial calcium uptake and we suggest that it can also be protective against neurodegeneration and development of dementia. Using primary co-culture neurons and astrocytes we studied the effect of Tg-2112x and its derivative Tg-2113x on β-amyloid-induced changes in calcium signal, mitochondrial membrane potential, mitochondrial calcium, and cell death. We have found that both compounds had no effect on β-amyloid or acetylcholine-induced calcium changes in the cytosol although Tg2113x, but not Tg2112x reduced glutamate-induced calcium signal. Both compounds were able to reduce mitochondrial calcium uptake and protected cells against β-amyloid-induced mitochondrial depolarization and cell death. Behavioral effects of Tg-2113x on learning and memory in fear conditioning were also studied in 3 mouse models of neurodegeneration: aged (16-month-old) C57Bl/6j mice, scopolamine-induced amnesia (3-month-old mice), and 9-month-old 5xFAD mice. It was found that Tg-2113x prevented age-, scopolamine- and cerebral amyloidosis-induced decrease in fear conditioning. In addition, Tg-2113x restored fear extinction of aged mice. Thus, reduction of the mitochondrial calcium uptake protects neurons and astrocytes against β-amyloid-induced cell death and contributes to protection against dementia of different ethology. These compounds could be used as background for the developing of a novel generation of disease-modifying neuroprotective agents.

Indexed as

Alzheimer DiseaseNeurotoxicity SyndromesAmyloid beta-PeptidesAnimalsCalciumDisease Models, AnimalExtinction, PsychologicalFearMiceMice, Inbred C57BLMice, TransgenicScopolamine DerivativesAmyloid beta-PeptidesCalciumScopolamine Derivatives

Identifiers

PMID35896565
PMCPMC9329451
OpenAlexW4288752157

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.